Lina Rosengren-Hovee, MD, MPH, assistant professor of medicine and infectious diseases, discussed long-acting PrEP agents versus Oral TDF-FTC in Medscape Medical News.
“We’re constantly searching for new modalities to expand our repertoire of what we can provide patients, especially those folks with the highest need for PrEP,” Rosengren-Hovee told Medscape Medical News.
“Being able to offer an injectable option is going to be a game changer, but it will be critical to pinpoint structural factors that affect adherence,” she added.